Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Soham D. Puvvada, Hongli Li, Lisa M. Rimsza, Steven H. Bernstein, Richard I. Fisher, Michael LeBlanc, Monika Schmelz, Betty Glinsmann-Gibson, Thomas P. Miller, Anne-Marie Maddox, Jonathan W. Friedberg, Sonali M. Smith & Daniel O. Persky. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leukemia & Lymphoma 57:10, pages 2359-2369.
Read now
Read now
Hans G. Drexler, Sonja Eberth, Stefan Nagel & Roderick A. F. MacLeod. (2016) Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas. Leukemia & Lymphoma 57:5, pages 1015-1020.
Read now
Read now
Jane Houldsworth, Marina Petlakh, Adam B. Olshen & R. S. K. Chaganti. (2008) Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of response. Leukemia & Lymphoma 49:11, pages 2170-2180.
Read now
Read now
Katia Lacrima, Andrea Rinaldi, Sara Vignati, Vittoria Martin, Maria Grazia Tibiletti, Gianluca Gaidano, Carlo V. Catapano & Francesco Bertoni. (2007) Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leukemia & Lymphoma 48:1, pages 158-167.
Read now
Read now
Jennifer L Tomlin, Barbara-Ann Guinn, Linda Z Penn & Neil L Berinstein. (2005) Bcl-2 and c-Myc co-operate in the Epstein – Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity. Leukemia & Lymphoma 46:4, pages 581-592.
Read now
Read now
Michelle Kim, Marcela V. Gronda, Hans A. Messner & James R. Ballinger. (2000) Accumulation of Sestamibi in Lymphoma Cell Lines In Vitro. Leukemia & Lymphoma 38:5-6, pages 599-603.
Read now
Read now
Articles from other publishers (30)
Mathew R. Schnorenberg, Katrina M. Hawley, Anika T. Thomas-Toth, Elyse A. Watkins, Yu Tian, Jeffrey M. Ting, Logan B. Leak, Isadora M. Kucera, Michal M. Raczy, Andrew L. Kung, Jeffrey A. Hubbell, Matthew V. Tirrell & James L. LaBelle. (2023) Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma. ACS Nano.
Crossref
Crossref
Jessie S. Kroonen, Ilona J. de Graaf, Sumit Kumar, Dennis F. G. Remst, Anne K. Wouters, Mirjam H. M. Heemskerk & Alfred C. O. Vertegaal. (2023) Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies. Leukemia 37:4, pages 864-876.
Crossref
Crossref
Adam Ustaszewski, Julia Paczkowska, Joanna Janiszewska, Stephan H. Bernhart, Julia Bein, Núria Russiñol, Martin-Leo Hansmann, Vicente Chapaprieta, José I. Martín-Subero, Reiner Siebert, Sylvia Hartmann & Maciej Giefing. (2023) Identification of two unannotated miRNAs in classic Hodgkin lymphoma cell lines. PLOS ONE 18:3, pages e0283186.
Crossref
Crossref
Prashanthi Dharanipragada & Nita Parekh. (2023) In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines. Cells 12:4, pages 596.
Crossref
Crossref
Weixin Wang, Rui Chen, Stephenie Droll, Emily Barber, Layla Saleh, Meghan Corrigan-Cummins, Megan Trick, Vollter Anastas, Nga Voong Hawk, Zhen Zhao, Donald C Vinh, Amy Hsu, Dennis D Hickstein, Steven M Holland & Katherine R Calvo. (2022) miR-181c regulates MCL1 and cell survival in GATA2 deficient cells. Journal of Leukocyte Biology 111:4, pages 805-816.
Crossref
Crossref
Martina Vockerodt, Katerina Vrzalikova, Maha Ibrahim, Eszter Nagy, Sandra Margielewska, Robert Hollows, Lauren Lupino, Reuben Tooze, Matthew Care, William Simmons, Alexandra Schrader, Tracey Perry, Maizaton Abdullah, Stephen Foster, Gary Reynolds, Alexander Dowell, Zbigniew Rudzki, Daniel Krappmann, Dieter Kube, Ciaran Woodman, Wenbin Wei, Graham Taylor & Paul G Murray. (2019) Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC‐subtype diffuse large B‐cell lymphoma. The Journal of Pathology 248:2, pages 142-154.
Crossref
Crossref
Dong Hoon Lee, Go Woon Kim & So Hee Kwon. (2019) The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Molecular Carcinogenesis 58:6, pages 944-956.
Crossref
Crossref
J. Scott Lee, Andrew Roberts, Dennis Juarez, Thanh-Trang T. Vo, Shruti BhattLee-or HerzogSharmila MallyaRichard J. Bellin, Suresh K. AgarwalAhmed Hamed Salem, Tu XuJia JiaLingxiao LiJohn R. HannaMatthew S. DavidsAngela G. Fleischman, Susan O’BrienLloyd T. Lam, Joel D. Leverson, Anthony LetaiJonathan H. Schatz & David A. Fruman. (2018) Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine 10:445.
Crossref
Crossref
Tabea ErdmannPavel KlenerJames T. LynchMichael GrauPetra VočkováJan MolinskyDiana TuskovaKevin HudsonUrszula M. PolanskaMichael GrondineMichele MayoBeiying DaiMatthias PfeiferKristian ErdmannDaniela SchwammbachMyroslav ZapukhlyakAnnette M. StaigerGerman OttWolfgang E. Berdel, Barry R. DaviesFrancisco CruzaleguiMarek TrnenyPeter Lenz, Simon T. BarryGeorg Lenz. (2017) Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 130:3, pages 310-322.
Crossref
Crossref
Gerda Brunhofer-Bolzer, Trang Le, Nils Dyckmanns, Hanna A. Knaus, Clemens Pausz, Patricia Freund, Ulrich Jäger, Thomas Erker & Katrina Vanura. (2015) SAR-Guided Development and Characterization of a Potent Antitumor Compound toward B-Cell Neoplasms with No Detectable Cytotoxicity toward Healthy Cells. Journal of Medicinal Chemistry 58:3, pages 1244-1253.
Crossref
Crossref
Ying Cai, Wenli Cui, Weixiang Chen, Ping Wei, Yayun Chi, Ping Zhang, Rui Bi & Xiaoyan Zhou. (2013) The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell International 13:1.
Crossref
Crossref
Thomas Clozel, ShaoNing Yang, Rebecca L. Elstrom, Wayne Tam, Peter Martin, Matthias Kormaksson, Samprit Banerjee, Aparna Vasanthakumar, Biljana Culjkovic, David W. Scott, Sarah Wyman, Micheal Leser, Rita Shaknovich, Amy Chadburn, Fabrizio Tabbo, Lucy A. Godley, Randy D. Gascoyne, Katherine L. Borden, Giorgio Inghirami, John P. Leonard, Ari Melnick & Leandro Cerchietti. (2013) Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. Cancer Discovery 3:9, pages 1002-1019.
Crossref
Crossref
Zhi-Zhang Yang, Deanna M. Grote, Steven C. Ziesmer, Bing Xiu, Nicole R. Yates, Frank J. Secreto, Lucy S. Hodge, Thomas E. Witzig, Anne J. Novak & Stephen M. Ansell. (2013) Soluble and Membrane-Bound TGF-β-Mediated Regulation of Intratumoral T Cell Differentiation and Function in B-Cell Non-Hodgkin Lymphoma. PLoS ONE 8:3, pages e59456.
Crossref
Crossref
Sang-Woo Kim, Deepak Rai & Ricardo C.T. Aguiar. (2011) Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma. Clinical Cancer Research 17:21, pages 6723-6732.
Crossref
Crossref
Harvey A. Greisman, Noah G. Hoffman & Hye Son Yi. (2011) Rapid High-Resolution Mapping of Balanced Chromosomal Rearrangements on Tiling CGH Arrays. The Journal of Molecular Diagnostics 13:6, pages 621-633.
Crossref
Crossref
Jeremy S. Abramson, Wen Chen, Przemyslaw Juszczynski, Hidenobu Takahashi, Donna Neuberg, Jeffery L. Kutok, Kunihiko Takeyama & Margaret A. Shipp. (2009) The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. British Journal of Haematology 144:3, pages 358-366.
Crossref
Crossref
Leandro C. Cerchietti, Jose M. Polo, Gustavo F. Da Silva, Pedro Farinha, Rita Shaknovich, Randy D. Gascoyne, Steven F. Dowdy & Ari Melnick. (2008) Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. Cancer Research 68:9, pages 3361-3369.
Crossref
Crossref
Denise M. Ray, Kimberly M. Morse, Shannon P. Hilchey, Tatiana M. Garcia, Raymond E. Felgar, Sanjay B. Maggirwar, Richard P. Phipps & Steven H. Bernstein. (2006) The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor γ-independent pathway. Experimental Hematology 34:9, pages 1201-1210.
Crossref
Crossref
C. Annette Hollmann, Trevor Owens, Josephine Nalbantoglu, Thomas J. Hudson & Robert Sladek. (2006) Constitutive Activation of Extracellular Signal-Regulated Kinase Predisposes Diffuse Large B-Cell Lymphoma Cell Lines to CD40-Mediated Cell Death. Cancer Research 66:7, pages 3550-3557.
Crossref
Crossref
Kazuyasu Fujii, Tadashi Kondo, Hideki Yokoo, Tesshi Yamada, Yoshihiro Matsuno, Keiji Iwatsuki & Setsuo Hirohashi. (2005) Protein expression pattern distinguishes different lymphoid neoplasms. PROTEOMICS 5:16, pages 4274-4286.
Crossref
Crossref
Sean P. Cregan, Nicole A. Arbour, Jason G. MacLaurin, Steven M. Callaghan, Andre Fortin, Eric C. C. Cheung, Daniel S. Guberman, David S. Park & Ruth S. Slack. (2004) p53 Activation Domain 1 Is Essential for PUMA Upregulation and p53-Mediated Neuronal Cell Death. The Journal of Neuroscience 24:44, pages 10003-10012.
Crossref
Crossref
Melinda S. Gordon, Cindy M. Kanegai, Jeanette R. Doerr & Randolph Wall. (2003)
Somatic hypermutation of the B cell receptor genes
B29
(
Ig
β, CD79b) and
mb1
(
Ig
α, CD79a)
. Proceedings of the National Academy of Sciences 100:7, pages 4126-4131.
Crossref
Crossref
Ryan S. Robetorye, Sandra D. Bohling, John W. Morgan, G. Chris Fillmore, Megan S. Lim & Kojo S.J. Elenitoba-Johnson. (2002) Microarray Analysis of B-Cell Lymphoma Cell Lines with the t(14;18). The Journal of Molecular Diagnostics 4:3, pages 123-136.
Crossref
Crossref
Sukvarsha Mehra, Hans Messner, Mark Minden & R.S.K. Chaganti. (2001) Molecular cytogenetic characterization of non‐Hodgkin lymphoma cell lines. Genes, Chromosomes and Cancer 33:3, pages 225-234.
Crossref
Crossref
. 2001. The Leukemia-Lymphoma Cell Line FactsBook. The Leukemia-Lymphoma Cell Line FactsBook
695
.
. 2001. The Leukemia-Lymphoma Cell Line FactsBook. The Leukemia-Lymphoma Cell Line FactsBook
680
686
.
Hans G. Drexler. 2001. The Leukemia-Lymphoma Cell Line FactsBook. The Leukemia-Lymphoma Cell Line FactsBook
250
.
Vadim G. DyominNallasivam PalanisamyKenneth O. LloydKaterina DyominaSuresh C. JhanwarJane HouldsworthR. S. K. Chaganti. (2000) MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95:8, pages 2666-2671.
Crossref
Crossref
HG Drexler, S Fombonne, Y Matsuo, Z-B Hu, H Hamaguchi & CC Uphoff. (2000) p53 alterations in human leukemia–lymphoma cell lines: in vitroartifact or prerequisite for cell immortalization?. Leukemia 14:1, pages 198-206.
Crossref
Crossref
Sadhana A. Samant & Rachel D. Sheppard. (1999) Mutational analysis of transgenic mouse B cell lymphomas: indication of a Trp53-independent pathway in tumor progression. Leukemia Research 23:10, pages 939-946.
Crossref
Crossref